News >

EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC

Jason M. Broderick @jasoncology
Published: Friday, Oct 18, 2019

Jonathan Cheng, MD

Jonathan Cheng, MD

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab (Keytruda) as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) and PD-L1 expression (composite positive score [CPS] ≥1) on their tumors.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication